Healthcare [ 4/11 ] | Drug Manufacturers—Specialty & Generic [ 29/112 ]
US | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 18, 23 | -0.71 Increased by +5.33% | -0.51 Decreased by -76.89% |
| May 15, 23 | -0.71 Decreased by -57.78% | -0.51 Decreased by -76.89% |
| Mar 31, 23 | -0.54 Increased by +36.47% | -0.33 Decreased by -192.84% |
| Mar 21, 23 | -0.59 Increased by 0.00% | -0.33 Decreased by -238.75% |
| Nov 14, 22 | -0.75 Decreased by -25.00% | -0.40 Decreased by -218.75% |
| Jul 27, 22 | -0.45 Decreased by -162.50% | -0.55 Increased by +33.06% |
| May 9, 22 | -0.85 Decreased by -34.92% | -0.69 Decreased by -33.61% |
| Feb 24, 22 | -0.59 Decreased by -227.78% | -0.42 Decreased by -96.37% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 23 | 13.55 M Increased by +13.85% | -8.30 M Decreased by -6.93% | Decreased by -61.28% Increased by +6.08% |
| Dec 31, 22 | 14.03 M Increased by +0.50% | -3.78 M Increased by +7.94% | Decreased by -26.94% Increased by +8.40% |
| Sep 30, 22 | 13.60 M Increased by +11.89% | -5.26 M Decreased by -25.68% | Decreased by -38.66% Decreased by -12.32% |
| Jun 30, 22 | 14.60 M Decreased by -32.71% | -3.12 M Decreased by -141.18% | Decreased by -21.33% Decreased by -161.19% |
| Mar 31, 22 | 11.90 M Increased by +6.10% | -7.76 M Decreased by -112.80% | Decreased by -65.25% Decreased by -100.57% |
| Dec 31, 21 | 13.96 M Increased by +1.34% | -4.11 M Decreased by -320.27% | Decreased by -29.41% Decreased by -314.70% |
| Sep 30, 21 | 12.15 M Decreased by -2.57% | -4.18 M Decreased by -576.86% | Decreased by -34.42% Decreased by -594.68% |
| Jun 30, 21 | 21.70 M Increased by +116.21% | 7.57 M Increased by +397.13% | Increased by +34.86% Increased by +237.43% |
Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.